Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
Go back to Positive Top-Line Results From Pfizer’s Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis| Pfizer Inc. (NYSE: PFE) | Delayed: 28.45 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $28.45 | 52 Week High | $37.39 | |||
| Open | $28.45 | 52 Week Low | $28.25 | |||
| Day High | $28.45 | P/E | 17.24 | |||
| Day Low | $28.45 | EPS | $1.65 | |||
| Volume | 25,048 | |||||
